Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,409 across all filing types
Latest filing 2024-03-20 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2024-03-20 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - FEVRIER 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers". It provides a table detailing the total number of shares and voting rights as of a specific date (February 29, 2024), referencing French regulatory articles (Code de commerce and AMF General Regulation). This content specifically relates to the total voting rights and share capital structure, which is a mandatory periodic disclosure in France. This type of disclosure, focusing purely on share capital and voting rights, is not explicitly covered by the primary definitions like 10-K, ER, or IR. It is a specific regulatory disclosure concerning the capital structure. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it deals with the capital structure, although this is a periodic disclosure of the *current* structure rather than an announcement of a *change*. However, given the highly specific nature of the French regulatory requirement cited (L. 233-8 II), and the lack of a dedicated code for 'Total Voting Rights Disclosure', it must be classified based on the closest thematic match or the fallback. Since it is a formal regulatory disclosure about the share count, SHA is the most appropriate category related to capital structure, even if it's a routine update. It is not an announcement of a report (RPA/RNS) because it contains the actual data, not just a link to it. Confidence is high due to the clear regulatory context.
2024-03-15 French
Sanofi: Information concerning the total number of voting rights and shares - February 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it concerns the 'total number of voting rights and shares' pursuant to French commercial code and AMF regulations. It provides a table detailing the total number of issued shares and the corresponding number of voting rights as of a specific date (February 29, 2024). This type of mandatory disclosure regarding the capital structure and voting power is a specific regulatory filing, but it does not fit perfectly into the provided definitions for 10-K, IR, or ER. It is a specific regulatory disclosure related to share capital and voting rights. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it deals directly with the number of shares and voting rights, which are fundamental components of the capital structure. It is not a general announcement of a report (RPA/RNS), but the data itself.
2024-03-15 English
S-8 POS
Regulatory Filings
2024-03-15 English
6-K
Regulatory Filings
2024-02-27 English
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
Earnings Release Classification · 92% confidence The document is explicitly titled '# **Press Release**' and details positive Phase 2 clinical trial results for a drug (rilzabrutinib) in treating Chronic Spontaneous Urticaria (CSU). It includes key efficacy data, safety profiles, quotes from management and external experts, and concludes with boilerplate information about the company (Sanofi) and forward-looking statements. This structure is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since it focuses on clinical trial results and pipeline updates rather than comprehensive quarterly financial performance (which would be an ER or IR), and it is not a formal regulatory filing like a 10-K or AR, the most appropriate classification is Earnings Release (ER), as these often include pipeline updates alongside financial highlights, or it could be considered a general announcement. Given the focus on clinical data presentation at a conference, it strongly aligns with the type of announcement often bundled with or preceding an Earnings Release, or standing alone as a major operational update. Since 'ER' covers initial announcements of periodical financial results (which often include pipeline news), and there isn't a specific 'Clinical Trial Result Announcement' code, ER is the closest fit for a major, time-sensitive corporate announcement of this nature, although it lacks explicit quarterly financial figures. However, if we strictly follow the definitions, this is a press release announcing clinical data, which is a significant corporate event. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal regulatory filing. Given the context of financial reporting databases, major clinical trial updates are often categorized under the broader 'Earnings Release' umbrella if they are not part of a formal report, or sometimes under 'Regulatory Filings' (RNS) if they are mandatory disclosures. Since it is a press release announcing data presented at a medical meeting, and it is not a short announcement linking to a full report (ruling out RPA/RNS based on length and content), 'ER' is the best fit for a major, time-sensitive corporate update, even if financial figures are sparse. I will assign ER based on the format and purpose of communicating key operational progress. FY 2024
2024-02-24 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.